Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 4, 2021, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2021.

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results

Pasadena. CA | Posted on April 16th, 2021

Conference Call and Webcast Details

Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm . For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 3080187.

A replay of the webcast will be available on the company’s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 3080187.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “plan,” “project,” “could,” “estimate,” or “continue” are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our businesses, or other characterizations of future events or circumstances are forward-looking statements. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the continuing impact of the COVID-19 pandemic, the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Media:
LifeSci Communications, LLC
Josephine Belluardo, Ph.D.
646-751-4361

www.lifescicommunications.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Biology’s hardest working pigments and ‘MOFs’ might just save the climate: A range of processes that currently depend on fossil fuels but are really hard to electrify will depend on the development of genuinely clean fuels, and for that to happen, much more efficient catalysts wi July 22nd, 2022

Generating power where seawater and river water meet July 22nd, 2022

First electric nanomotor made from DNA material: Synthetic rotary motors at the nanoscale perform mechanical work July 22nd, 2022

At the water’s edge: Self-assembling 2D materials at a liquid–liquid interface: Scientists find a simple way to produce heterolayer coordination nanosheets, expanding the diversity of 2D materials July 22nd, 2022

Nanomedicine

How different cancer cells respond to drug-delivering nanoparticles: The findings of a large-scale screen could help researchers design nanoparticles that target specific types of cancer July 22nd, 2022

Biology’s hardest working pigments and ‘MOFs’ might just save the climate: A range of processes that currently depend on fossil fuels but are really hard to electrify will depend on the development of genuinely clean fuels, and for that to happen, much more efficient catalysts wi July 22nd, 2022

Study reveals new mode of triggering immune responses July 15th, 2022

UNC Charlotte-led team invents new anticoagulant platform, offering hope for advances for heart surgery, dialysis, other procedures July 15th, 2022

Announcements

Quantum computer works with more than zero and one: Quantum digits unlock more computational power with fewer quantum particles July 22nd, 2022

Biology’s hardest working pigments and ‘MOFs’ might just save the climate: A range of processes that currently depend on fossil fuels but are really hard to electrify will depend on the development of genuinely clean fuels, and for that to happen, much more efficient catalysts wi July 22nd, 2022

Generating power where seawater and river water meet July 22nd, 2022

First electric nanomotor made from DNA material: Synthetic rotary motors at the nanoscale perform mechanical work July 22nd, 2022

Financial Reports

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

180 Degree Capital Corp. to Report Fourth Quarter 2020 Financial Results on Monday, February 22, 2021 and to Host a Conference Call on Tuesday, February 23, 2021 February 19th, 2021

Events/Classes

CEA & Partners Present ‘Powerful Step Towards Industrialization’ Of Linear Si Quantum Dot Arrays Using FDSOI Material at VLSI Symposium: Invited paper reports 3-step characterization chain and resulting methodologies and metrics that accelerate learning, provide data on device pe June 17th, 2022

June Conference in Grenoble, France, to Explore Pathways to 6G Applications, Including ‘Internet of Senses’, Sustainability, Extended Reality & Digital Twin of Physical World: Organized by CEA-Leti, the Joint EuCNC and 6G Summit Sees Telecom Sector as an ‘Enabler for a Sustainabl June 1st, 2022

How a physicist aims to reduce the noise in quantum computing: NAU assistant professor Ryan Behunin received an NSF CAREER grant to study how to reduce the noise produced in the process of quantum computing, which will make it better and more practical April 1st, 2022

Could quantum technology be New Mexico’s next economic boon? Quantum New Mexico Coalition aims to establish state as national hub April 1st, 2022

Nanobiotechnology

How different cancer cells respond to drug-delivering nanoparticles: The findings of a large-scale screen could help researchers design nanoparticles that target specific types of cancer July 22nd, 2022

Biology’s hardest working pigments and ‘MOFs’ might just save the climate: A range of processes that currently depend on fossil fuels but are really hard to electrify will depend on the development of genuinely clean fuels, and for that to happen, much more efficient catalysts wi July 22nd, 2022

First electric nanomotor made from DNA material: Synthetic rotary motors at the nanoscale perform mechanical work July 22nd, 2022

Study reveals new mode of triggering immune responses July 15th, 2022

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project